# US 2014/0275088 A1 · Small molecule malarial aldolase-trap enhancers and glideosome inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0275088 A1
- Document ID: US20140275088A1
- Status: Published application
- Kind: A1
- Application number: 14/353,438
- Filed: 2012-10-25
- Published: 2014-09-18
- Earliest claimed: 2011-10-25
- Assignees: New York University; The Johns Hopkins University
- Applicants: New York University; Johns Hopkins University
- Inventors: Timothy J. Cardozo; Jürgen Bosch; Sondra Maureen Nemetski
- Web page: https://patentgrep.com/patent/US20140275088A1

## CPC

- C07C 249/16: of hydrazones
- C07C 235/78: the carbon skeleton containing rings
- C07C 243/18: containing rings
- C07D 207/337: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 215/14: Radicals substituted by oxygen atoms
- C07D 239/46: Two or more oxygen, sulphur or nitrogen atoms
- C07D 239/47: One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C07D 239/54: as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D 271/12: condensed with carbocyclic rings or ring systems
- C07D 277/34: Oxygen atoms
- C07D 333/24: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 487/04: Ortho-condensed systems
- C12Q 1/527: involving lyase
- G16B 5/00: ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B 15/00: ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
- G16B 15/30: Drug targeting using structural data; Docking or binding prediction
- G01N 2333/44: from protozoa
- G01N 2333/445: Plasmodium
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

In one aspect, the present invention relates to a method of identifying compounds useful in modifying the activity of Aldolase. The method includes providing a first model comprising Aldolase or residues of the amino acid sequence corresponding to SEQ ID NO: 1 said residues being at amino acid positions selected from the group consisting of 10-13, 26, 27, 29, 30, 31, 32, 33, 37, 39, 40, 41, 43, 44, 47, 48, 51, 52, 60, 63, 66, 79, 84, 85, 92, 93, 103, 106-109, 112-117, 138, 142, 146, 148, 151, 153, 179, 182, 183, 185, 186, 194, 196, 197, 198, 199, 208, 226-228, 231-269, 270, 272, 277-283, 285-289, 294, 295, 297-299, 301-304, 306-310 312, 313, 316, 317, 319, 321, 323, 326, 330, 344, 345, and 347, providing one or more candidate compounds, evaluating contact between the candidate compounds and the first model to determine which of the one or more candidate compounds have an ability to bind to and/or fit in the first model, and identifying compounds which, based on said evaluating, have the ability to bind to and/or fit in the first model as compounds potentially useful for modifying the activity of Aldolase. The present invention also discloses compounds and compositions which modify the activity of Aldolase, or a complex between Aldolase and TRAP. Methods of treating or preventing malaria, or an infection by apicomplexan organisms are also disclosed.

## Claims

### Claim 1

A method of identifying compounds useful in modifying the activity of Aldolase, said method comprising:
providing a first model comprising Aldolase or residues of the amino acid sequence corresponding to SEQ ID NO: 1 said residues being at amino acid positions selected from the group consisting of 10-13, 26, 27, 29, 30, 31, 32, 33, 37, 39, 40, 41, 43, 44, 47, 48, 51, 52, 60, 63, 66, 79, 84, 85, 92, 93, 103, 106-109, 112-117, 138, 142, 146, 148, 151, 153, 179, 182, 183, 185, 186, 194, 196, 197, 198, 199, 208, 226-228, 231-269, 270, 272, 277-283, 285-289, 294, 295, 297-299, 301-304, 306-310, 312, 313, 316, 317, 319, 321, 323, 326, 330, 344, 345, and 347;
providing one or more candidate compounds;
evaluating contact between the candidate compounds and the first model to determine which of the one or more candidate compounds have an ability to bind to and/or fit in the first model; and
identifying compounds which, based on said evaluating, have the ability to bind to and/or fit in the first model as compounds potentially useful for modifying the activity of Aldolase.

### Claim 2 (depends on 1)

The method according to claim 1 further comprising:
screening the identified compounds in vitro for their ability to kill and/or inhibit growth of an apicomplexan organism and
designating the screened compounds which kill and/or inhibit an apicomplexan organism as a therapeutics targeting apicomplexan organisms.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the Aldolase is derived from an apicomplexan organism.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the apicomplexan organism is selected from the group consisting of Plasmodium falciparum, Plasmodium yoelii, Plasmodium chabaudi, Plasmodium berghei, Plasmodium knowlesi, Plasmodium vivax, Plasmodium vinckei, Theileria annulata, Theileria parva, Babesia bovis, Cryptosporidium parvum, Cryptosporidium hominis, Toxoplasma gondii, Cyclospora cayetanensis, Isospora belli, Sarcocystis spp., and Eimeria spp.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said evaluating comprises using automated docking algorithms.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said evaluating involves analyzing electrostatic complementarity, vander Waals interactions, hydrophilic interactions, hydrophobic interactions, and/or hydrogen bonding between the candidate compounds and the first model.

### Claim 7 (depends on 1)

The method according to claim 1 further comprising:
designing de novo compounds based on said identifying.

### Claim 8 (depends on 7)

The method according to claim 7, wherein said designing comprises:
linking functional groups or small molecule fragments of the identified compounds to form de novo compounds.

### Claim 9

A method of identifying compounds useful in stabilizing a complex between Aldolase and thrombospondin-related anonymous protein (TRAP) or a portion thereof, said method comprising:
providing a complex of first model comprising Aldolase or residues of the amino acid sequence corresponding to SEQ ID NO: 1 said residues being at amino acid positions selected from the group consisting of 10-13, 26, 27, 29, 30, 31, 32, 33, 37, 39, 40, 41, 43, 44, 47, 48, 51, 52, 60, 63, 66, 79, 84, 85, 92, 93, 103, 106-109, 112-117, 138, 142, 146, 148, 151, 153, 179, 182, 183, 185, 186, 194, 196, 197, 198, 199, 208, 226-228, 231-269, 270, 272, 277-283, 285-289, 294, 295, 297-299, 301-304, 306-310, 312, 313, 316, 317, 319, 321, 323, 326, 330, 344, 345, and 347; and a second model comprising TRAP or residues of the amino acid sequence corresponding to SEQ ID NO: 38 said residues being at amino acid positions selected from the group consisting of 554, 555, 556, 557, 558, and 559;
providing one or more candidate compounds;
examining contact between the candidate compounds and the complex between the first and the second model to determine which of the one or more candidate compounds have an ability to bind to and/or fit in the complex between the first and the second model; and
identifying compounds which, based on said examining, have the ability to bind to and/or fit in the complex between the first and the second model as compounds potentially useful for stabilizing the complex.

### Claim 10 (depends on 9)

The method according to claim 9 further comprising:
screening the identified compounds in vitro for their ability to kill and/or inhibit growth of an apicomplexan organism and
designating the screened compounds which kill and/or inhibit an apicomplexan organism as a therapeutic targeting apicomplexan organisms.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the Aldolase is derived from an apicomplexan organism.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the thrombospondin-related anonymous protein (TRAP) is derived from an apicomplexan organism.

### Claim 13 (depends on 11)

The method according to claim 11, wherein the apicomplexan organism is selected from the group consisting of Plasmodium falciparum, Plasmodium yoelii, Plasmodium chabaudi, Plasmodium berghei, Plasmodium knowlesi, Plasmodium vivax, Theileria annulata, Theileria parva, Babesia bovis, Cryptosporidium parvum, Cryptosporidium hominis, Toxoplasma gondii, Cyclospora cayetanensis, Isospora belli, Sarcocystis spp., and Eimeria spp.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the apicomplexan organism is selected from the group consisting of Plasmodium falciparum, Plasmodium yoelii, Plasmodium chabaudi, Plasmodium berghei, Plasmodium knowlesi, Plasmodium vivax, Theileria annulata, Theileria parva, Babesia bovis, Cryptosporidium parvum, Cryptosporidium hominis, Toxoplasma gondii, Cyclospora cayetanensis, Isospora belli, Sarcocystis spp., and Eimeria spp.

### Claim 15 (depends on 9)

The method according to claim 9, wherein said examining comprises using automated docking algorithms.

### Claim 16 (depends on 9)

The method according to claim 9, wherein said examining involves analyzing electrostatic complementarity, vander Waals interactions, hydrophobic interactions, hydrophilic interactions, and/or hydrogen bonding between the candidate compounds and the complex.

### Claim 17 (depends on 9)

The method according to claim 9 further comprising:
designing de novo compounds based on said identifying.

### Claim 18 (depends on 17)

The method according to claim 17, wherein said designing comprises:
linking functional groups or small molecule fragments of the identified compounds to form de novo compounds.

### Claim 19

A pharmaceutical composition comprising:
a pharmaceutical carrier and
a compound selected from the group consisting of:
(1) a compound of formula (I)
wherein:
n is an integer from 0 to 4;
m is an integer from 0 to 4;
R1a is independently at each occurrence H, halogen, CF3, CHF2, CH2F, OH, NH2, CN, NO2, —C(O)R5a, —SR5a, —S(O)R5a, —S(O)2R5a, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; or
two adjacent R1a groups may combine to form a 3- to 7-membered heterocyclic ring containing from 1 to 5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
R2a is independently H, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
R3a is independently H, —SR5a, —S(O)R5a, —S(O)2R5a, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
R4a is independently at each occurrence H, halogen, CF3, CHF2, CH2F, OH, OR5a, O(CH2)2OR5a, —C(O)R5a, —OC(O)R5a, —NHC(O)R5a, —NHC(O)OR5a—C(O)OR5a, —C(O)NR5aR6a, —NHR5a, —NR5aR6a, —SR5a, —S(O)R5a, —S(O)2R5a, NH2, CN, NO2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, mono or polycyclic aryl;
two adjacent R4a groups may combine to form a 3- to 7-membered heterocyclic ring containing from 1 to 5 heteroatoms selected from the group consisting of oxygen, nitrogen, sulfur, and bismuth, wherein heterocycyclic ring can be unsaturated or saturated and optionally substituted with from 1-2 substituents independently selected at each occurrence thereof from OH, F and C1-C6 alkyl;
R5a and R6a are independently H, CHF2, CH2Ph, CH2C(O)NH2, CH2CH2NHSO2Me, C1-C16 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, a monocyclic aryl or a monocyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and wherein CH2Ph is optionally substituted with from 1-3 substituents independently selected at each occurrence thereof from F, Cl, OMe; and
A is a substituted or unsubstituted mono or polycyclic aryl or substituted or unsubstituted mono or polycyclic heteroaryl containing from 1 to 5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
(2) a compound of formula (II)
wherein:
X is O, S, or NH;
n is an integer from 0 to 3;
m is an integer from 0 to 3;
R1b is independently H, halogen, CF3, CHF2, CH2F, OH, NH2, CN, NO2, OR5b, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
R2b and R3b is independently H, —SR5b, —S(O)R5b, —S(O)2R5b, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
R4b is independently at each occurrence H, halogen, CF3, CHF2, CH2F, OH, OR5b, —C(O)R5b, —C(O)OR5b, —C(O)NR5bR6b, —NHR5b, —NR5bR6b, —SR5b, —S(O)R5b, —S(O)2R5b, NH2, CN, NO2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, mono or polycyclic aryl; and
R5b and R6b are independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, a monocyclic aryl or a monocyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, each monocyclic aryl or monocyclic heteroaryl optionally substituted from 1 to 4 times with substituents selected from the group consisting of H, halogen, CF3, CHF2, CH2F, OH, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, and C4-C7 cycloalkylalkyl;
(3) a compound of formula (III):
wherein:
m, n, and p are independently integers from 0 to 3;
R1c is H, —SR3c, —S(O)R3c, —S(O)2R3c, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
R2c is independently at each occurrence H, halogen, CF3, CHF2, CH2F, OH, OR3c, —C(O)R3c, —C(O)OR3c, —C(O)NR3cR4c, —NHR3c, —NR3cR4c, —SR3c, —S(O)R3c, —S(O)2R3c, NH2, CN, NO2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, mono or polycyclic aryl; and
R1c and R4c are independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, a monocyclic aryl or a monocyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
(4) a compound of formula (IV):
wherein:
m and n are integers from 0 to 3;
X and Y are independently O or S;
R1d and R4d are independently at each occurrence H, halogen, CF3, CHF2, CH2F, OH, OR5d, —C(O)R5d, —C(O)OR5d, —C(O)NR5dR6d, —NHR5d, —NR5dR6d, —SR5d, —S(O)R5d, —S(O)2R5d, NH2, CN, NO2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, mono or polycyclic aryl;
R2d and R3d are independently H, —SR5d, —S(O)R5d, —S(O)2R5d, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and
R5d and R6d are independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, a monocyclic aryl or a monocyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
(5) a compound of formula V:
wherein:
m is an integer from 0 to 3 and
R1e is independently at each occurrence H, halogen, CF3, CHF2, CH2F, OH, OR5e, —C(O)R5e, —C(O)OR5e, —C(O)NR5eR6e, —NHR5e, —NR5eR6e, —SR5e, —S(O)R5e, —S(O)2R5e, NH2, CN, NO2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, mono or polycyclic aryl or mono or polycyclic heterocycle containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur.

### Claim 20 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the selected compound has the formula (I):
wherein:
n is an integer from 0 to 4;
m is an integer from 0 to 4;
R1a is independently at each occurrence H, halogen, CF3, CHF2, CH2F, OH, NH2, CN, NO2, —C(O)R5a, —SR5a, —S(O)R5a, —S(O)2R5a, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; or
two adjacent R1a groups may combine to form a 3- to 7-membered heterocyclic ring containing from 1 to 5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
R2a is independently H, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
R3a is independently H, —SR5a, —S(O)R5a, —S(O)2R5a, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
R4a is independently at each occurrence H, halogen, CF3, CHF2, CH2F, OH, OR5a, O(CH2)2OR5a, —C(O)R5a, —OC(O)R5a, —NHC(O)R5a, —NHC(O)OR5a, —C(O)OR5a, —C(O)NR5aR6a, —NHR5a, —NR5aR6a, —SR5a, —S(O)R5a, —S(O)2R5a, NH2, CN, NO2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, mono or polycyclic aryl;
two adjacent R4a groups may combine to form a 3- to 7-membered heterocyclic ring containing from 1 to 5 heteroatoms selected from the group consisting of oxygen, nitrogen, sulfur, and bismuth, wherein heterocycyclic ring can be unsaturated or saturated and optionally substituted with from 1-2 substituents independently selected at each occurrence thereof from OH, F and C1-C6 alkyl;
R5a and R6a are independently H, CHF2, CH2Ph, CH2C(O)NH2, CH2CH2NHSO2Me, C1-C16 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, a monocyclic aryl or a monocyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and wherein CH2Ph is optionally substituted with from 1-3 substituents independently selected at each occurrence thereof from F, Cl, OMe; and
A is a substituted or unsubstituted mono or polycyclic aryl or substituted or unsubstituted mono or polycyclic heteroaryl containing from 1 to 5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur.

### Claim 21 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the selected compound has the formula (I):
wherein:
n is an integer from 0 to 3;
m is an integer from 0 to 3;
R1a is independently at each occurrence H, halogen, CF3, CHF2, CH2F, OH, NH2, CN, NO2, —SR5a, —S(O)R5a, —S(O)2R5a, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; or
two adjacent R1a groups may combine to form a 3- to 7-membered heterocyclic ring containing from 1 to 5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
R2a is independently H, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
R3a is independently H, —SR5a, —S(O)R5a, —S(O)2R5a, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
R4a is independently at each occurrence H, halogen, CF3, CHF2, CH2F, OH, OR5a, —C(O)R5a, —C(O)OR5a, —C(O)NR5aR6a, —NHR5a, —NR5aR6a, —SR5a, —S(O)R5a, —S(O)2R5a, NH2, CN, NO2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, mono or polycyclic aryl;
R5a and R6a are independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, a monocyclic aryl or a monocyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and
A is a substituted or unsubstituted mono or polycyclic aryl or substituted or unsubstituted mono or polycyclic heteroaryl containing from 1 to 5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur.

### Claim 22 (depends on 19)

A pharmaceutical composition according to claim 19, wherein the selected compound has the formula (II):
wherein:
X is O, S, or NH;
n is an integer from 0 to 3;
m is an integer from 0 to 3;
Rib is independently H, halogen, CF3, CHF2, CH2F, OH, NH2, CN, NO2, OR5b, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
R2b and R3b is independently H, —SR5b, —S(O)R5b, —S(O)2R5b, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
R4b is independently at each occurrence H, halogen, CF3, CHF2, CH2F, OH, OR5b, —C(O)R5b, —C(O)OR5b, —C(O)NR5bR6b, —NHR5b, —NR5bR6b, —SR5b, —S(O)R5b, —S(O)2R5b, NH2, CN, NO2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, mono or polycyclic aryl; and
R5b and R6b are independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, a monocyclic aryl or a monocyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, each monocyclic aryl or monocyclic heteroaryl optionally substituted from 1 to 4 times with substituents selected from the group consisting of H, halogen, CF3, CHF2, CH2F, OH, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, and C4-C7 cycloalkylalkyl.

### Claim 23 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the selected compound has the formula (III):
wherein:
m, n, and p are independently integers from 0 to 3;
R1c is H, —SR3c, —S(O)R3c, —S(O)2R3c, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;
R2c is independently at each occurrence H, halogen, CF3, CHF2, CH2F, OH, OR3c, —C(O)R3c, —C(O)OR3c, —C(O)NR3cR4c, —NHR3c, —NR3cR4c, —SR3c, —S(O)R3c, —S(O)2R3c, NH2, CN, NO2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, mono or polycyclic aryl; and
R3c and R4c are independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, a monocyclic aryl or a monocyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur.

### Claim 24 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the selected compound has the formula (IV):
wherein:
m and n are integers from 0 to 3;
X and Y are independently O or S;
R1d and R4d are independently at each occurrence H, halogen, CF3, CHF2, CH2F, OH, OR5d, —C(O)R5d, —C(O)OR5d, —C(O)NR5dR6d, —NHR5d, —NR5dR6d, —SR5d, —S(O)R5d, —S(O)2R5d, NH2, CN, NO2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, mono or polycyclic aryl;
R2d and R3d are independently H, —SR5d, —S(O)R5d, —S(O)2R5d, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, aryl C1-C6 alkyl, mono or polycyclic aryl, or mono or polycyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and
R5d and R6d are independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, a monocyclic aryl or a monocyclic heteroaryl containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur.

### Claim 25 (depends on 19)

The pharmaceutical composition according to claim 19, wherein the selected compound has the formula (V):
wherein:
m is an integer from 0 to 3 and
R1e is independently at each occurrence H, halogen, CF3, CHF2, CH2F, OH, OR5e, —C(O)R5e, —C(O)OR5e, —C(O)NR5eR6e, —NHR5e, —NR5eR6e, —SR5e, —S(O)R5e, —S(O)2R5e, NH2, CN, NO2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 cycloalkylalkyl, mono or polycyclic aryl or mono or polycyclic heterocycle containing from 1-5 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur.

### Claim 26 (depends on 19)

A method of modifying activity of Aldolase in an apicomplexan organism, said method comprising:
providing an apicomplexan organism;
providing a pharmaceutical composition according to claim 19;
contacting the pharmaceutical composition with the apicomplexan organism, wherein said contacting modifies the activity of Aldolase in the apicomplexan organism.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the activity of Aldolase is inhibited.

### Claim 28 (depends on 26)

The method according to claim 26, wherein the activity of Aldolase is enhanced.

### Claim 29 (depends on 26)

The method according to claim 26, wherein the apicomplexan organism is selected from the group consisting of Plasmodium falciparum, Plasmodium yoelii, Plasmodium chabaudi, Plasmodium berghei, Plasmodium knowlesi, Plasmodium vivax, Theileria annulata, Theileria parva, Babesia bovis, Cryptosporidium parvum, Cryptosporidium hominis, Toxoplasma gondii, Cyclospora cayetanensis, Isospora belli, Sarcocystis spp., and Eimeria spp.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the apicomplexan organism is Plasmodium falciparum.

### Claim 31 (depends on 19)

A method of stabilizing a complex between Aldolase or portions thereof and thrombospondin-related anonymous protein (TRAP) or portions thereof, said method comprising:
providing an apicomplexan organism;
providing a pharmaceutical composition according to claim 19; and
contacting the pharmaceutical composition with the apicomplexan organism under conditions effective to stabilize the complex between Aldolase or portions thereof and thrombospondin-related anonymous protein (TRAP) or portions thereof.

### Claim 32 (depends on 31)

The method according to claim 31, wherein the apicomplexan organism is selected from the group consisting of Plasmodium falciparum, Plasmodium yoelii, Plasmodium chabaudi, Plasmodium berghei, Plasmodium knowlesi, Plasmodium vivax, Plasmodium vinckei, Theileria annulata, Theileria parva, Babesia bovis, Cryptosporidium parvum, Cryptosporidium hominis, Toxoplasma gondii, Cyclospora cayetanensis, Isospora belli, Sarcocystis spp., and Eimeria spp.

### Claim 33 (depends on 32)

The method according to claim 32, wherein the apicomplexan organism is Plasmodium falciparum.

### Claim 34 (depends on 19)

A method of inhibiting dissociation of cytoplasmic TRAP tail from glideosome in an apicomplexan organism comprising:
providing an apicomplexan organism;
providing a pharmaceutical composition according to claim 19;
contacting the pharmaceutical composition with the apicomplexan organism under condition effective to inhibit the dissociation of cytoplasmic TRAP tail from the glideosome.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the apicomplexan organism is selected from the group consisting of Plasmodium falciparum, Plasmodium yoelii, Plasmodium chabaudi, Plasmodium berghei, Plasmodium knowlesi, Plasmodium vivax, Theileria annulata, Theileria parva, Babesia bovis, Cryptosporidium parvum, Cryptosporidium hominis, Toxoplasma gondii, Cyclospora cayetanensis, Isospora belli, Sarcocystis spp., and Eimeria spp.

### Claim 36 (depends on 35)

The method according to claim 35, wherein the apicomplexan organism is Plasmodium falciparum.

### Claim 37 (depends on 19)

A method of inhibiting activity and/or survival of an apicomplexan organism, said method comprising:
selecting apicomplexan organism and
administering to the selected apicomplexan organism a pharmaceutical composition according to claim 19 under conditions effective to inhibit the activity and/or survival of the apicomplexan organism.

### Claim 38 (depends on 37)

The method according to claim 37, wherein the apicomplexan organism is selected from the group consisting of Plasmodium falciparum, Plasmodium yoelii, Plasmodium chabaudi, Plasmodium berghei, Plasmodium knowlesi, Plasmodium vivax, Plasmodium vinckei, Theileria annulata, Theileria parva, Babesia bovis, Cryptosporidium parvum, Cryptosporidium hominis, Toxoplasma gondii, Cyclospora cayetanensis, Isospora belli, Sarcocystis spp., and Eimeria spp.

### Claim 39 (depends on 38)

The method according to claim 38, wherein the apicomplexan organism is Plasmodium falciparum.

### Claim 40 (depends on 37)

The method according to claim 37, wherein the administering is carried out in vivo.

### Claim 41 (depends on 19)

A method a treating or preventing infection caused by an apicomplexan organism in a subject, said method comprising:
selecting a subject having or susceptible to an infection caused by an apicomplexan organism and
administering to the selected subject a pharmaceutical composition according to claim 19 under conditions effective to prevent or treat the infection caused by an apicomplexan organism.

### Claim 42 (depends on 41)

The method according to claim 41, wherein the apicomplexan organism is selected from the group consisting of Plasmodium falciparum, Plasmodium yoelii, Plasmodium chabaudi, Plasmodium berghei, Plasmodium knowlesi, Plasmodium vivax, Plasmodium vinckei, Theileria annulata, Theileria parva, Babesia bovis, Cryptosporidium parvum, Cryptosporidium hominis, Toxoplasma gondii, Cyclospora cayetanensis, Isospora belli, Sarcocystis spp., and Eimeria spp.

### Claim 43 (depends on 42)

The method according to claim 42, wherein the apicomplexan organism is Plasmodium falciparum.

### Claim 44 (depends on 41)

The method according to claim 41, wherein the administering is carried out in vivo.

### Claim 45 (depends on 41)

The method according to claim 41, wherein the said administering is carried out orally, topically, transdermally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, or by application to mucous membranes.

### Claim 46

A method of treating or preventing malarial infection in a subject comprising:
selecting a subject susceptible to or having the malarial infection;
providing a compound which binds to and/or fits in:
a) a first model comprising Aldolase or residues of the amino acid sequence corresponding to SEQ ID NO: 1 being at amino acid positions selected from the group consisting of 10-13, 26, 27, 29, 30, 31, 32, 33, 37, 39, 40, 41, 43, 44, 47, 48, 51, 52, 60, 63, 66, 79, 84, 85, 92, 93, 103, 106-109, 112-117, 138, 142, 146, 148, 151, 153, 179, 182, 183, 185, 186, 194, 196, 197, 198, 199, 208, 226-228, 231-269, 270, 272, 277-283, 285-289, 294, 295, 297-299, 301-304, 306-310, 312, 313, 316, 317, 319, 321, 323, 326, 330, 344, 345, and 347; and/or
b) a complex between said first model and a second model comprising a thrombospondin-related anonymous protein (TRAP) or residues of the amino acid sequence corresponding to SEQ ID NO: 38 said residues being at amino acid positions selected from the group consisting of 554, 555, 556, 557, 558, and 559; and
administering the compound to the selected subject under conditions effective to treat the malarial infection in the subject.

### Claim 47 (depends on 46)

The method according to claim 46, wherein the administering is carried out in vivo.

### Claim 48 (depends on 46)

The method according to claim 46, wherein the said administering is carried out orally, topically, transdermally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, or by application to mucous membranes.

### Claim 49 (depends on 46)

The method according to claim 46, wherein the subject is a mammal.

### Claim 50 (depends on 49)

The method according to claim 49, wherein the subject is human.
